Related Experiment Video

Updated: Aug 15, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Genetic polymorphism of CYP2A6 in the German population

M Bourian1, H Gullstén, W Legrum

  • 1Institute of Pharmacology and Toxicology, Philipps University of Marburg, Karl-von-Frisch-Strasse 1, 35034, Marburg, Germany.

Toxicology
|April 27, 2000
PubMed

Insights

Genetic variations in drug-metabolizing enzymes (DME) impact drug safety and efficacy. This study focuses on CYP2A6 genetic polymorphism and genotyping methods in the German population.

Area of Science:

  • Pharmacogenomics
  • Enzyme kinetics
  • Molecular biology

Background:

  • Genetic polymorphism in drug-metabolizing enzymes (DME) significantly influences pharmacotherapy outcomes, leading to toxicity or treatment failure.
  • Individual susceptibility to chemically induced cancers and other diseases can be linked to genetically determined differences in metabolic enzyme activity.
  • Cytochrome P450 (CYP450) enzymes are crucial for xenobiotic oxidation, with CYP2A6 being a key isoform.

Purpose of the Study:

  • To provide an updated summary of genetic polymorphism in the CYP2A6 enzyme.
  • To emphasize and comparatively analyze genotyping techniques for CYP2A6.
  • To evaluate the sensitivity and specificity of these genotyping methods using data from the German population.

Main Methods:

  • Literature review and synthesis of existing data on CYP2A6 genetic polymorphism.
  • Comparative analysis of various CYP2A6 genotyping techniques.
  • Evaluation of genotyping method performance metrics (sensitivity, specificity) in a specific population.

Main Results:

  • Detailed overview of known CYP2A6 genetic variants and their functional impact.
  • Comparison of different genotyping strategies, highlighting their strengths and limitations.
  • Assessment of the clinical applicability and accuracy of CYP2A6 genotyping in the German population.

Conclusions:

  • Understanding CYP2A6 genetic polymorphism is vital for personalized medicine and predicting drug response.
  • Accurate and efficient genotyping techniques are essential for clinical implementation.
  • Population-specific data, like that from the German population, is crucial for validating genotyping methods.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...